Faivre S - Search Results

1

Molecular basis for sunitinib efficacy and future clinical development.

Faivre S, Demetri G, Sargent W, Raymond E. Faivre S, et al. Nat Rev Drug Discov. 2007 Sep;6(9):734-45. doi: 10.1038/nrd2380. Nat Rev Drug Discov. 2007. PMID: 17690708 Review.

2

mTOR-targeted therapy of cancer with rapamycin derivatives.

Vignot S, Faivre S, Aguirre D, Raymond E. Vignot S, et al. Among authors: faivre s. Ann Oncol. 2005 Apr;16(4):525-37. doi: 10.1093/annonc/mdi113. Epub 2005 Feb 22. Ann Oncol. 2005. PMID: 15728109 Review.

3

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E. Faivre S, et al. J Clin Oncol. 2006 Jan 1;24(1):25-35. doi: 10.1200/JCO.2005.02.2194. Epub 2005 Nov 28. J Clin Oncol. 2006. PMID: 16314617 Clinical Trial.

4

Current development of mTOR inhibitors as anticancer agents.

Faivre S, Kroemer G, Raymond E. Faivre S, et al. Nat Rev Drug Discov. 2006 Aug;5(8):671-88. doi: 10.1038/nrd2062. Nat Rev Drug Discov. 2006. PMID: 16883305

5

New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

Faivre S, Djelloul S, Raymond E. Faivre S, et al. Semin Oncol. 2006 Aug;33(4):407-20. doi: 10.1053/j.seminoncol.2006.04.005. Semin Oncol. 2006. PMID: 16890796 Review.

6

Preclinical and clinical development of novel agents that target the protein kinase C family.

Serova M, Ghoul A, Benhadji KA, Cvitkovic E, Faivre S, Calvo F, Lokiec F, Raymond E. Serova M, et al. Among authors: faivre s. Semin Oncol. 2006 Aug;33(4):466-78. doi: 10.1053/j.seminoncol.2006.04.009. Semin Oncol. 2006. PMID: 16890801 Review.

7

[Irinotecan and liver dysfunctions].

Sablin MP, Le Tourneau C, Faivre S, Raymond E. Sablin MP, et al. Among authors: faivre s. Therapie. 2007 Mar-Apr;62(2):111-5. doi: 10.2515/therapie:2007024. Epub 2007 Jun 21. Therapie. 2007. PMID: 17582311 French.

8

Lessons learned in the development of targeted therapy for malignant gliomas.

Omuro AM, Faivre S, Raymond E. Omuro AM, et al. Among authors: faivre s. Mol Cancer Ther. 2007 Jul;6(7):1909-19. doi: 10.1158/1535-7163.MCT-07-0047. Mol Cancer Ther. 2007. PMID: 17620423 Review.

9

Could we expect to improve survival in small cell lung cancer?

El Maalouf G, Rodier JM, Faivre S, Raymond E. El Maalouf G, et al. Among authors: faivre s. Lung Cancer. 2007 Aug;57 Suppl 2:S30-4. doi: 10.1016/S0169-5002(07)70425-7. Lung Cancer. 2007. PMID: 17686444 Review.

10

[Gemcitabine and pemetrexed: novel associations and mechanisms of resistance].

Sablin MP, Le Tourneau C, El Maalouf G, Raymond E, Faivre S. Sablin MP, et al. Among authors: faivre s. Bull Cancer. 2007;94 Spec No Actualites:S149-54. Bull Cancer. 2007. PMID: 17845986 Review. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results